Limits...
The expression of aldehyde dehydrogenase 1 (ALDH1) in ovarian carcinomas and its clinicopathological associations: a retrospective study.

Huang R, Li X, Holm R, Trope CG, Nesland JM, Suo Z - BMC Cancer (2015)

Bottom Line: Statistical analyses showed that high ALDH1 expression in tumor cells was significantly associated with histological subtypes, early FIGO stage, well differentiation grade and better survival probability (p < 0.05).The expression of ALDH1 in the stromal cells had no clinicopathological associations in the present study (p > 0.05).More studies are warranted to find out the mechanisms for this.

View Article: PubMed Central - PubMed

Affiliation: Departments of Pathology, The Norwegian Radium Hospital, Oslo University Hospital, Ullernchausseen 70, 0379, Oslo, Norway.

ABSTRACT

Background: Aldehyde dehydrogenase 1 (ALDH1) is widely used as a specific cancer stem cell marker in a variety of cancers, and may become a promising target for cancer therapy. However, the role of its expression in tumor cells and the microenvironment in different cancers is still controversial.

Methods: To clarify the clinicopathological effect of ALDH1 expression in ovarian carcinoma, a series of 248 cases of paraffin-embedded formalin fixed ovarian carcinoma tissues with long term follow-up information were studied by immunohistochemistry.

Results: The immunostaining of ALDH1was variably detected in both tumor cells and the stromal cells, although the staining in tumor cells was not as strong as that in stromal cells. Statistical analyses showed that high ALDH1 expression in tumor cells was significantly associated with histological subtypes, early FIGO stage, well differentiation grade and better survival probability (p < 0.05). The expression of ALDH1 in the stromal cells had no clinicopathological associations in the present study (p > 0.05).

Conclusioms: High expression of cancer stem cell marker ALDH1 in ovarian carcinoma cells may thus portend a favorable prognosis, but its expression in tumor microenvironment may have no role in tumor behavior of ovarian carcinomas. More studies are warranted to find out the mechanisms for this.

No MeSH data available.


Related in: MedlinePlus

Survival probabilities in different ALDH1 expression groups. a Survival plot disclosed that ALDH1 high expression in tumor cells in ovarian carcinomas had a better OS than the low expression and Negative groups (p < 0.05, Kaplan-Meier). b High expression level of ALDH1 in tumor cells in ovarian carcinomas was significantly associated with high PFS probabilities (p < 0.05, Kaplan-Meier). c The expression level of ALDH1 in the stromal cells in ovarian carcinoma had no significant association with OS probabilities (p > 0.05, Kaplan-Meier). d No statistical association was found between the expression of ALDH1 in the stromal cells of ovarian carcinoma and the PFS probabilities (p > 0.05, Kaplan-Meier).
© Copyright Policy - open-access
Related In: Results  -  Collection

License 1 - License 2
getmorefigures.php?uid=PMC4494797&req=5

Fig2: Survival probabilities in different ALDH1 expression groups. a Survival plot disclosed that ALDH1 high expression in tumor cells in ovarian carcinomas had a better OS than the low expression and Negative groups (p < 0.05, Kaplan-Meier). b High expression level of ALDH1 in tumor cells in ovarian carcinomas was significantly associated with high PFS probabilities (p < 0.05, Kaplan-Meier). c The expression level of ALDH1 in the stromal cells in ovarian carcinoma had no significant association with OS probabilities (p > 0.05, Kaplan-Meier). d No statistical association was found between the expression of ALDH1 in the stromal cells of ovarian carcinoma and the PFS probabilities (p > 0.05, Kaplan-Meier).

Mentions: In the 232 patients, ALDH1 expression in tumor cells was negative in 86 cases, low in 108 cases and high in 38 cases. The median OSs in the ALDH1 tumor-negative group, tumor low-expression group and tumor high-expression group were 1.440 years, 1.330 years and 3.000 years, respectively. The median PFSs in the above three groups were 0.590 year, 0.580 year and 1.050 years, respectively. Furthermore, ALDH1 expression in ovarian carcinoma cells was significantly associated with better OS and PFS by statistical analyses (p < 0.05, Kaplan-Meier method, Fig. 2a, b).Fig. 2


The expression of aldehyde dehydrogenase 1 (ALDH1) in ovarian carcinomas and its clinicopathological associations: a retrospective study.

Huang R, Li X, Holm R, Trope CG, Nesland JM, Suo Z - BMC Cancer (2015)

Survival probabilities in different ALDH1 expression groups. a Survival plot disclosed that ALDH1 high expression in tumor cells in ovarian carcinomas had a better OS than the low expression and Negative groups (p < 0.05, Kaplan-Meier). b High expression level of ALDH1 in tumor cells in ovarian carcinomas was significantly associated with high PFS probabilities (p < 0.05, Kaplan-Meier). c The expression level of ALDH1 in the stromal cells in ovarian carcinoma had no significant association with OS probabilities (p > 0.05, Kaplan-Meier). d No statistical association was found between the expression of ALDH1 in the stromal cells of ovarian carcinoma and the PFS probabilities (p > 0.05, Kaplan-Meier).
© Copyright Policy - open-access
Related In: Results  -  Collection

License 1 - License 2
Show All Figures
getmorefigures.php?uid=PMC4494797&req=5

Fig2: Survival probabilities in different ALDH1 expression groups. a Survival plot disclosed that ALDH1 high expression in tumor cells in ovarian carcinomas had a better OS than the low expression and Negative groups (p < 0.05, Kaplan-Meier). b High expression level of ALDH1 in tumor cells in ovarian carcinomas was significantly associated with high PFS probabilities (p < 0.05, Kaplan-Meier). c The expression level of ALDH1 in the stromal cells in ovarian carcinoma had no significant association with OS probabilities (p > 0.05, Kaplan-Meier). d No statistical association was found between the expression of ALDH1 in the stromal cells of ovarian carcinoma and the PFS probabilities (p > 0.05, Kaplan-Meier).
Mentions: In the 232 patients, ALDH1 expression in tumor cells was negative in 86 cases, low in 108 cases and high in 38 cases. The median OSs in the ALDH1 tumor-negative group, tumor low-expression group and tumor high-expression group were 1.440 years, 1.330 years and 3.000 years, respectively. The median PFSs in the above three groups were 0.590 year, 0.580 year and 1.050 years, respectively. Furthermore, ALDH1 expression in ovarian carcinoma cells was significantly associated with better OS and PFS by statistical analyses (p < 0.05, Kaplan-Meier method, Fig. 2a, b).Fig. 2

Bottom Line: Statistical analyses showed that high ALDH1 expression in tumor cells was significantly associated with histological subtypes, early FIGO stage, well differentiation grade and better survival probability (p < 0.05).The expression of ALDH1 in the stromal cells had no clinicopathological associations in the present study (p > 0.05).More studies are warranted to find out the mechanisms for this.

View Article: PubMed Central - PubMed

Affiliation: Departments of Pathology, The Norwegian Radium Hospital, Oslo University Hospital, Ullernchausseen 70, 0379, Oslo, Norway.

ABSTRACT

Background: Aldehyde dehydrogenase 1 (ALDH1) is widely used as a specific cancer stem cell marker in a variety of cancers, and may become a promising target for cancer therapy. However, the role of its expression in tumor cells and the microenvironment in different cancers is still controversial.

Methods: To clarify the clinicopathological effect of ALDH1 expression in ovarian carcinoma, a series of 248 cases of paraffin-embedded formalin fixed ovarian carcinoma tissues with long term follow-up information were studied by immunohistochemistry.

Results: The immunostaining of ALDH1was variably detected in both tumor cells and the stromal cells, although the staining in tumor cells was not as strong as that in stromal cells. Statistical analyses showed that high ALDH1 expression in tumor cells was significantly associated with histological subtypes, early FIGO stage, well differentiation grade and better survival probability (p < 0.05). The expression of ALDH1 in the stromal cells had no clinicopathological associations in the present study (p > 0.05).

Conclusioms: High expression of cancer stem cell marker ALDH1 in ovarian carcinoma cells may thus portend a favorable prognosis, but its expression in tumor microenvironment may have no role in tumor behavior of ovarian carcinomas. More studies are warranted to find out the mechanisms for this.

No MeSH data available.


Related in: MedlinePlus